Search the Newsreel

Backblaze (NASDAQ:BLZE) Given New $25.00 Price Target at Oppenheimer

Azenta earnings on deck: Can life sciences firm return to profit?

Azenta Inc. is scheduled to report its fiscal third-quarter earnings, with analysts expecting a return to profitability at $0.10 per share on $149.29 million in revenue, a significant improvement from the previous quarter's loss. Investors will be closely watching for sustained profitability, North American …

Bristol Myers Squibb Potential Deal With AstraZeneca Seen Unlikely as Shareholder Views Diverge, RBC Says

Bristol Myers Squibb's (BMY) reported merger discussions with AstraZeneca (AZN) will unlikely result PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium news articles. Upgrade Already have a subscription? …

Brokers split on AstraZeneca merger talk as shares recover some ground

Brokers split on AstraZeneca merger talk as shares recover some ground Proactive uses images sourced from Shutterstock Citi has told clients that a large chunk of deal risk is already in AstraZeneca PLC's (LSE:AZN, NASDAQ:AZN) share price after Monday's sharp fall, while Deutsche Bank …

Backblaze, Inc. Q2 2026 Earnings Call Summary

Backblaze, Inc. Q2 2026 Earnings Call Summary - Moby Strategic Performance Drivers Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pick. Tap here. Performance beat …

AstraZeneca (LSE:AZN) Is In Merger Talks With Bristol Myers For $400 Billion

Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge. AstraZeneca (LSE:AZN) is reported to be in advanced merger talks with Bristol Myers Squibb. The potential deal could create a combined pharmaceutical company valued at about US$400b. …

AstraZeneca-Bristol Myers: The Floodgates for Biotech Mergers Are Open

Even if a megamerger fails to materialize, investors stand to benefit from a wave of M&A activity in the biopharma sector. Continue Reading

SOPHiA GENETICS Enters Collaboration to Develop Companion Diagnostics for Precision Oncology Therapies

BOSTON and ROLLE, Switzerland, Aug. 4, 2026 /PRNewswire/ -- SOPHiA GENETICS (NASDAQ: SOPH) today announced a new global collaboration to develop, validate, and deploy two companion diagnostics (CDx) supporting precision oncology therapies with AstraZeneca (LSE/STO/NYSE: AZN).SOPHiA GENETICS Logo This multi-year collaboration agreement will advance …

Backblaze Latest Results: Sales guidance raised to $172-174M range

Backblaze significantly raised its FY2026 sales guidance to $172.000 million-$174.000 million, exceeding analyst estimates and its previous projections. This upward revision indicates strong demand for its cloud storage services and improved operational momentum. The company's confidence in capturing market share and its pricing power …

Azenta (NASDAQ:AZTA) Reports Upbeat Q2 CY2026

Azenta (NASDAQ:AZTA) Reports Upbeat Q2 CY2026 Life sciences company Azenta (NASDAQ:AZTA) announced better-than-expected revenue in Q2 CY2026, with sales up 12% year on year to $161.2 million. Its non-GAAP profit of $0.16 per share was 60% above analysts' consensus estimates. Is now the time …

Why Backblaze Stock Jumped Today

Key Points Backblaze is winning new customers and earning more business from existing clients. AI is boosting demand for the company's highly scalable storage solutions.10 stocks we like better than Backblaze › Shares of Backblaze (NASDAQ: BLZE) rose sharply on Tuesday after the cloud …

The Bull Case For Azenta (AZTA) Could Change Following Its Latest Earnings And Revenue Turnaround - Learn Why

Azenta earnings beat by $0.06, revenue topped estimates

Azenta (NASDAQ:AZTA) Issues Quarterly Earnings Results, Beats Estimates By $0.05 EPS

Backblaze (NASDAQ:BLZE) Hits New 12-Month High Following Better-Than-Expected Earnings

BLZE Stock Hits A 55-Month High — CEO Says Backblaze Had An 'Amazing Quarter', CRWV Deal Impresses Wall Street

My AstraZeneca shares just crashed 9.7%! Here’s why I’m NOT selling

AstraZeneca shares dropped significantly due to rumors of a potential mega-merger with Bristol Myers Squibb and a failed late-stage trial for its heart disease program, Wainua. Despite these setbacks, an investor is not selling, viewing the decline as a market overreaction rather than a …

More Biotech M&A Is Coming, Whether an AstraZeneca-Bristol Myers Deal Happens or Not

Even if a megamerger fails to materialize, investors stand to benefit from a wave of M&A activity in the biopharma sector. Continue Reading

Backblaze files prospectus for resale of 4.19 million shares

Backblaze Inc. has filed an SEC prospectus for the resale of 4.19 million Class A common shares by an existing stockholder. This filing allows the shareholder to liquidate their position without the company issuing new shares or raising capital, meaning Backblaze will not receive …

Bristol-Myers Squibb, AstraZeneca deal talks remain active - report

A recent report indicates that deal talks between AstraZeneca and Bristol-Myers Squibb are still ongoing. Following this news, Bristol-Myers Squibb's shares saw a slight increase, while AstraZeneca's shares experienced a minor decline. This update follows an earlier Financial Times report about potential acquisition discussions.

AstraZeneca and Bristol-Myers Squibb: Megamerger Reports Leave Us Scratching Our Heads

Morningstar reports on the potential megamerger between Bristol-Myers Squibb and AstraZeneca, noting that such large acquisitions are rare in biopharma. While the deal could combine complementary patent portfolios and pipeline assets, concerns exist regarding integration challenges and regulatory hurdles due to overlapping oncology focuses. …

Earnings Flash (AZTA) Azenta, Inc. Reports Q3 Revenue $161.2M, vs. FactSet Est of $149.3M

Azenta, Inc. (AZTA) reported its Q3 revenue at $161.2 million, surpassing FactSet's estimate of $149.3 million. This financial news highlights a stronger-than-anticipated performance for the biotechnology and medical research company in its third fiscal quarter. The report also mentions other recent financial updates for …

Backblaze Q2 Earnings Call Highlights

Key Points Interested in Backblaze, Inc.? Here are five stocks we like better. Backblaze exceeded Q2 expectations: Revenue rose 18% year over year to $42.7 million, while adjusted EBITDA nearly doubled to $13 million and the margin reached 30%. B2 Cloud Storage accelerated: B2 …

Backblaze (NASDAQ: BLZE) files to register 4.19M CoreWeave warrant shares for resale

Backblaze (NASDAQ: BLZE) has filed an S-3 registration statement to allow CoreWeave, Inc. to resell up to 4.19 million shares of Class A common stock. These shares are issuable upon the exercise of two warrants, with exercise prices of $7.60 per share and expiry …

Beazer Homes (NYSE: BZH) SVP reports small tax-related share withholding

Michael Anthony Dunn, SVP, General Counsel, and Corporate Secretary of Beazer Homes (NYSE: BZH), had 328 shares of Common Stock withheld on August 1, 2026, to cover tax withholding obligations upon the vesting of restricted stock. The transaction, valued at $32.10 per share, was …

AstraZeneca Stock Plunges 7.7% on Reported $400 Billion Merger Talks

This article first appeared on GuruFocus. AstraZeneca (NYSE:AZN), a global pharmaceutical company developing cancer, rare-disease and other medicines, plunged approximately 7.7% in Monday's U.S. regular-session trading as investors assessed reported merger discussions with Bristol Myers Squibb (NYSE:BMY), a U.S. biopharmaceutical company. A combination could …

The $400 Billion Reason Bristol-Myers Squibb (BMY) Stock Is Up Today

Bristol-Myers Squibb (BMY) shares opened higher on Monday following reports that the U.S. pharma giant held preliminary merger talks with UK rival AstraZeneca (AZN). If finalized, this reported transaction would create the world's largest drugmaker (by revenue) with a market cap approaching $400 billion. …

Form 144 Maze Therapeutics For: 3 August By Investing.com

The article reports on a Form 144 filing by Maze Therapeutics for August 3rd. It is a brief news item from Investing.com, likely indicating an insider transaction or an intent to sell restricted stock by the company. The content also includes market data, other …

ParaZero Technologies (Nasdaq: PRZO) secures initial DefendAir order

ParaZero Technologies has secured an initial order for its DefendAir Net Pods from a Tier-1 European defense manufacturer. These Net Pods will be integrated into an autonomous Counter-UAS system to provide a net-based physical interception layer. This order highlights ParaZero's strategy of integrating its …

MAZE (NASDAQ: MAZE) insider trusts detail stock sales in Form 144

MAZE (NASDAQ: MAZE) has filed a Form 144 detailing proposed sales of its common stock, including 34,501 shares valued at over $922,000 through UBS Financial Services. The filing also reveals past transactions, specifically gifts from Jason Coloma in 2021, and recent open-market sales by …

ParaZero Technologies Ltd. Receives Initial DefendAir Order From Tier-1 European Defense Manufacturer

ParaZero Technologies Ltd. has secured an initial order for its DefendAir Net Pods from a prominent European defense manufacturer. These Net Pods will be integrated into an autonomous Counter-UAS system, allowing for controlled, net-based physical interception of drones. This order signifies an expansion of …

Top Healthcare Analyst: A $400 Billion AstraZeneca-Bristol Myers Deal Could “Cut Costs in a Big Way”

Quick Read BMY's existing $2B cost-savings program and discounted forward P/E of ~10 make it an attractive AZN acquisition target, Holz argues. Eli Lilly's $1 trillion market cap dwarfs all pharma rivals, pushing companies like Merck to pursue deals ahead of looming patent cliffs. …

AstraZeneca Investors See Little Logic in Bristol Tie-Up

AstraZeneca Plc investors had a clear message for the UK drugmaker on Monday: they don't like the idea of a $400 billion merger with Bristol-Myers Squibb Co. Bloomberg Intelligence's Director of Research, Sam Fazeli joins to discuss. View Comments

Stocks mixed as AstraZeneca merger talk dents FTSE 100

The FTSE 100 underperformed European peers on Monday as heavy falls in AstraZeneca outweighed more optimistic noises in the Middle East. The FTSE 100 index closed down 10.35 points, 0.1%, at 10,857.70. The FTSE 250 ended up 249.75 points, 1.0%, at 24,224.77, while the …

Azenta (AZTA) Stock Looks Undervalued On Sales But Fairly Valued On Cash Flow

Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. Azenta stock is coming off a difficult five year stretch, yet the valuation checks send a more balanced signal. The Discounted Cash Flow (DCF) intrinsic …

AstraZeneca shares slump after $400bn BMS merger rumours

Shares in AstraZeneca dropped by nearly 3% at market open after a report that the drugmaker is in talks with oncology rival Bristol Myers Squibb (BMS) regarding a mega-merger deal. According to the Financial Times (FT), which first reported the discussions, a tie-up would …